Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. (TDOC) reports that Jonathan Dorfman, Chief Legal Officer and Secretary, directly held 2,773 common shares as of November 2, 2026, alongside 232 performance stock units and restricted stock units tied to 1,668, 7,500, 5,001 and 10,000 common shares. The units convert one-for-one into common stock.
Teladoc Health, Inc. (TDOC) reported third-quarter 2026 revenue of $605.1 million, compared with $626.4 million a year earlier. Net loss narrowed to $26.9 million from $49.5 million, and Adjusted EBITDA, a company-defined non-GAAP measure, was $79.4 million versus $69.9 million. BetterHelp revenue was $206.6 million versus $236.9 million; Integrated Care revenue was $398.5 million versus $389.5 million.
Operating indicators moved in different directions: U.S. Integrated Care members totaled 100.1 million, down 2% year over year, while chronic care program enrollment rose 15% to 1.344 million. BetterHelp paying users declined 12% to 336,000. For the first nine months, revenue was $1.826 billion versus $1.888 billion, and operating cash flow was $180.6 million versus $206.6 million.
At September 30, cash and cash equivalents were $849.9 million. Teladoc had $1.0 billion principal outstanding on 1.25% convertible senior notes due June 1, 2027, and approximately $297.2 million available under its revolving credit facility, from which it had not drawn. The company said it was in compliance with facility covenants and expects approximately $20.0 million of pre-tax restructuring costs for full-year 2026.
Teladoc Health, Inc. (TDOC) reported third-quarter 2026 revenue of $605.1 million, down 3% from $626.4 million a year earlier, and a net loss of $26.9 million, compared with $49.5 million. Adjusted EBITDA, a non-GAAP measure, was $79.4 million, up 14%. Integrated Care revenue increased 2% to $398.5 million, while BetterHelp revenue fell 13% to $206.6 million; BetterHelp adjusted EBITDA margin was 2.2%, versus 1.6%.
Third-quarter operating cash flow was $106.5 million, compared with $99.3 million, and free cash flow was $75.9 million versus $67.9 million. For the first nine months, operating cash flow was $180.6 million versus $206.6 million, while free cash flow was $85.4 million versus $113.5 million. Teladoc expects full-year 2026 revenue of $2,395–$2,441 million, adjusted EBITDA of $277–$303 million, net loss per share of ($0.95)–($0.75), and free cash flow of $135–$165 million, based on current market conditions and expectations.
Teladoc Health, Inc. (TDOC) reported that Dimensional Fund Advisors had beneficial ownership of 9,100,047 common shares, or 5.0% of the class, as of September 30, 2026. The shares are owned by funds advised or managed by Dimensional, which disclaims beneficial ownership. Dimensional reported sole voting power over 8,935,731 shares and sole dispositive power over 9,100,047 shares; shared voting and dispositive power were both zero.
Teladoc Health, Inc. (TDOC) Chief Accounting Officer Joseph Ronald Catapano reported that 2,083 restricted stock units converted one-for-one into common shares on October 1, 2026. He sold 655 common shares on October 2, 2026, at $5.6530 per share to cover tax withholding related to vesting. His reported remaining balance was 8,335 restricted stock units. No Rule 10b5-1 plan is reported.
Teladoc Health, Inc. (TDOC) said Adam C. Vandervoort, its Chief Legal Officer and Secretary, informed the company of his decision to resign effective November 1, 2026. The company states that the resignation was made with good reason under his executive severance agreement. Following his departure, Jonathan Dorfman, currently Senior Vice President, Securities & Corporate Law, will assume both roles. Vandervoort will provide certain advisory services, including supporting the transition of his responsibilities to his successor, through November 1, 2027, without compensation.
Teladoc Health, Inc. (TDOC) reported that Chief Executive Officer and director Charles Divita III exercised equity awards and sold shares. On September 10, 2026, performance stock units for 3,642 shares and restricted stock units for 39,160 shares converted on a one-for-one basis into common stock. On September 11, 2026, he sold 17,805 common shares at $6.104 per share, with the filing stating the sale was to cover tax withholding obligations related to these vestings.
Teladoc Health, Inc. (TDOC) is the issuer for which Charles Divita III filed a notice of proposed sale of common stock under Rule 144. The notice covers a planned sale of 17,805 shares of Teladoc common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $108,683.50.
The shares relate to restricted stock vesting on September 10, 2026, and the filer notes that the sale includes an amount necessary to cover a tax obligation arising from the settlement of a vested equity award distribution. In the prior three months, Charles Divita reported additional Teladoc common stock sales totaling 36,401 shares for aggregate proceeds of $240,944.59.
Teladoc Health, Inc. (TDOC) reported that Carlos Nueno, President, International, had restricted stock units convert into a total of 13,273 shares of common stock on September 1, 2026, on a one-for-one basis. On September 2, 2026, he sold 6,200 shares at $6.301 per share, and a footnote states these shares were sold to cover the tax withholding obligation arising from the RSU vesting. No Rule 10b5-1 trading plan is reported.
Teladoc Health, Inc. (TDOC) reported insider equity activity by Chief Legal Officer and Secretary Adam C. Vandervoort. On September 1, 2026, his restricted stock units and performance stock units were converted into an aggregate of 14,928 shares of common stock on a one-for-one basis as vesting occurred. On September 2, 2026, he sold 7,573 shares of common stock at $6.301 per share, and a footnote states these shares were sold to cover the tax withholding obligation arising from the vesting of these awards. No Rule 10b5-1 trading plan is reported.